The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 108, Issue 7, 2014, Pages 397-404

  Teerawattananon, Yot ^a   Tritasavit, Nattha ^a   Suchonwanich, Netnapis ^b   Kingkaew, Pritaporn ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b National Health Security Office   (Thailand)

Author keywords

decision making; Health economic evaluation; reimbursement; Thailand

Indexed keywords

COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INTERPERSONAL COMMUNICATION; ORGANIZATION; PRACTICE GUIDELINE; PUBLIC HEALTH; REIMBURSEMENT; THAILAND;

COST-BENEFIT ANALYSIS; CROSS-CULTURAL COMPARISON; DECISION MAKING, ORGANIZATIONAL; DELIVERY OF HEALTH CARE; DRUG COSTS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH EXPENDITURES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; NEGOTIATING; REIMBURSEMENT MECHANISMS; THAILAND;

EID: 84940166599     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2014.06.017     Document Type: Article

References (12)

1. A. Towse, A. Mills, and V. Tangcharoensathien Learning from Thailand's health reforms BMJ 328 2004 103 105
2. V. Tangcharoensathien, S. Tantivess, Y. Teerawattananon, N. Auamkul, and P. Jongudoumsuk Universal coverage and its impact on reproductive health services in Thailand Reprod Health Matters 10 2002 59 69
3. Y. Teerawattananon, S. Russell, and M. Mugford A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 25 2007 467 479
4. S. Tantivess, Y. Teerawattananon, and A. Mills Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program Pharmacoeconomics 27 2009 931 945
5. S. Wibulpolprasert The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the national list of essential drugs J Med Assoc Thai 91 Suppl 2 2008 S1 S3
6. M. Thavorncharoensap, Y. Teerawattananon, S. Natanant, W. Kulpeng, J. Yothasamut, and P. Werayingyong Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res 5 2013 29 36
7. U. Chaikledkaew, C. Lertpitakpong, Y. Teerawattananon, M. Thavorncharoensap, and V. Tangcharoensathien The current capacity and future development of economic evaluation for policy decision-making: a survey among researchers and decision-makers in Thailand Value Health 12 Suppl 3 2009 S31 S35
8. A. Mohara, S. Youngkong, R.P. Velasco, P. Werayingyong, K. Pachanee, and P. Prakongsai Using health technology assessment for informing coverage decisions in Thailand J Comp Eff Res 1 2012 137 146
9. S. Youngkong, R. Baltussen, S. Tantivess, A. Mohara, and Y. Teerawattananon Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand Value Health 15 2012 961 970
10. Kasatsombul N, Skulbomrungsil R, Kanchanapibul I, Udomaugsorn S, Jitruknathee A. Research and Systems Development for National Drug Account. Nonthaburi: Food and Drug Administration; 2012. (Unpublished).
11. The National List of Essential Medicines Subcommittee. National List of Essential Medicines 2013. Nonthaburi: Food and Drug Administration; 2013. (Unpublished).
12. T. Jirawattanapisal, P. Kingkaew, T.J. Lee, and M.C. Yang Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand South Korea, and Taiwan. Value Health 12 Suppl 3 2009 S4 S11